Circular Genomics and PharmatrophiX have agreed to apply blood-based circular RNA profiling to LM11A-31, a small molecule targeting the p75 neurotrophin receptor, beginning with an open-label Alzheimer's biomarker study. The collaboration aims to characterize baseline molecular heterogeneity and track pathway-level change during treatment, integrating circRNA data with cognitive, imaging, proteomic and established Alzheimer's markers. For neurodegeneration, the practical value lies in identifying who responds and detecting biological movement earlier than clinical endpoints allow.
Key Points
- Blood circRNA profiling applied to p75 neurotrophin receptor drug LM11A-31
- Platform maps baseline heterogeneity and pharmacodynamic response during treatment
- Planned expansion includes HIV-associated dementia and progressive supranuclear palsy
Longevity Analysis
Circular RNAs are stable, enriched in neural tissue and measurable in blood, which makes them a plausible route to reading brain-level repair and degeneration without imaging or spinal fluid sampling. Responder biology is the central problem in neurodegeneration trials: populations defined by syndrome rather than molecular state dilute real signal, and a peripheral readout of pathway activity narrows that gap. The broader principle extends past drug development — accurate interpretation of what the nervous system is doing, early enough to act, determines whether regenerative interventions are applied to the people whose biology can respond to them.
Original published by Longevity.Technology.